CrossBridge Bio

CrossBridge Bio is developing next-generation antibody-drug conjugates (ADCs) to improve cancer treatment, starting with breast cancer. Its novel linker technology allows precise attachment of two drug payloads, optimizing effectiveness while reducing toxicity. By enhancing stability and targeting, CrossBridge Bio aims to create safer and more powerful ADC therapies.